Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab +/- Vorinostat in Recurrent Glioblastoma
NCT01266031Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2011
- Primary completion
- Jun 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vorinostat in glioblastoma (GBM), Gliosarcoma (GS) and malignant glioma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Progression Free Survival at 6 Months and Maximum Tolerated Dose of Oral Vorinostat Used With Bevacizumab at 28 days. Started Jul 2011; status: completed.
02
Drugs
vorinostat
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)malignant glioma
Beyond the preview
Go deeper on NCT01266031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266031.